Background-Many clinical trials have demonstrated a benefit for cardiac resynchronization (CRT) and implantable cardioverter-defibrillator (ICD) therapies in patients with heart failure and reduced ejection fraction, yet questions have been raised with regard to the benefit of ICDs for women. The purpose of this study was to determine the clinical effectiveness of CRT and ICD therapy as a function of sex in outpatients with heart failure and reduced ejection fraction (≤35%). Methods and Results-Data from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) were analyzed by device status and sex among guideline-eligible patients for vital status (alive/dead) at 24 months. Multivariate generalized estimating equation analyses were conducted adjusting for baseline patient and practice characteristics. In the ICD/CRT-defibrillator (CRT-D) eligible cohort (n=7748), there were 5485 (71%) men and 2261 (29%) women. In the CRT-pacemaker (CRT-P)/CRT-D eligible cohort (n=1188), there were 824 (69%) men and 364 (31%) women. The clinical benefit associated with ICD/CRT-D therapy was similar in both men and women (men adjusted odds ratio, 0.71; 95% confidence interval, 0.57-0.87; P=0.0012; and women adjusted odds ratio, 0.65; 95% confidence interval, 0.49-0.85; P=0.0019). For CRT-P/CRT-D, the associated benefits showed no significant heterogeneity (men adjusted odds ratio, 0.59; 95% confidence interval, 0.33-1.06; P=0.0793; and women adjusted odds ratio, 0.44; 95% confidence interval, 0.22-0.90; P=0.0243). The device-by-sex interactions were not significant (P=0.4441 for CRT-P/CRT-D and P=0.5966 for ICD/CRT-D). Conclusions-The use of guideline-directed CRT and ICD therapy was associated with substantially reduced 24-month mortality in eligible men and women with heart failure and reduced ejection fraction. Device therapies should be offered to all eligible patients with heart failure, without modification based on sex. (Circ Heart Fail. 2014;7:146-153.) 
I mplantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) have been demonstrated to improve clinical outcomes in select patients with heart failure (HF) with reduced ejection fraction (EF) in multiple clinical trials. [1] [2] [3] [4] [5] [6] [7] However, recent questions have been raised with regard to the benefits of these devices in women and race/ethnic minority groups in part attributable to the fact that these populations have been under-represented in many clinical trials. 8, 9 In a recent meta-analysis, ICD therapy for the primary prevention of sudden cardiac death in women was not shown to reduce all-cause mortality. 10 On the contrary, the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) trial showed that CRT-D therapy compared with ICD was associated with greater benefit in women when compared with men. 11 And, although an analysis of the Sudden Death in Heart Failure (SCD-HeFT) trial found a smaller ICD benefit for women, the test for an interaction between sex and therapy was not significant. 12 Moreover, multiple studies have demonstrated large sex-based gaps in the implementation of evidenced-based, guideline-directed device therapy for HF. [13] [14] [15] [16] [17] It is still unclear whether women with HF receiving ICD and CRT devices in addition to medical therapy in routine clinical practice have better outcomes than women with HF receiving medical therapy alone.
The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) cohort provides an opportunity to offer insight into these remaining questions regarding the benefit of device therapy in women outpatients with HF. The purpose of this study was to determine the clinical effectiveness of CRT-D and ICD therapy as a function of sex in outpatients with HF and low EF (≤35%).
Methods

Study Overview
This study is a prespecified analysis of IMPROVE HF, a prospective observational cohort study of 15 177 patients diagnosed with HF (or prior myocardial infarction) and reduced left ventricular EF (LVEF) being treated at outpatient cardiology (including multispecialty) practices. The primary objective of the IMPROVE HF program was to evaluate the effects of a practice-specific performance improvement initiative on the adherence to guideline-recommended therapies. The methods and primary results of the IMPROVE HF have been previously reported. 18 Briefly, community and academic outpatient cardiology/multispecialty practices were invited to participate. All sites were required to obtain institutional review board approval or waivers before enrollment. Patients with a primary or secondary diagnosis of HF or prior myocardial infarction with left ventricular systolic dysfunction who were aged ≥18 years at the time of the most recent office visit were eligible for enrollment. Participants in the study were required to have an LVEF ≤35% as measured by the most recent echocardiogram, nuclear multiple gated acquisition scan, contrast ventriculogram, MRI, or a qualitative assessment of left ventricular function indicative of moderate-to-severe dysfunction. Patients who met the guideline-specified eligibility criteria for each individual therapy, with no contraindications, intolerance, or other documented reasons for not receiving the therapy, were eligible for inclusion in the analyses for that measure. For this analysis, study participants were required to be eligible for ICD/CRT-D or CRT-P/CRT-D therapy. Eligibility for ICDs was based on a primary prevention indication, and CRT eligibility criteria were based on the American College of Cardiology/ American Heart Association/Heart Rhythm Society guidelines from 2005, 2008, and 2009. [19] [20] [21] Documentation of QRS duration and New York Heart Association functional class consistent with guideline specifications was required to be considered eligible for ICD/CRT-D or CRT-P/CRT-D therapy; thus, only patients with QRS duration documented were included in analyses for CRT-P/CRT-D therapy. The primary end point was vital status (alive/dead) at 24-month follow-up.
Patients were not eligible to participate in the IMPROVE HF if they were not expected to survive for 12 months because of medical conditions other than HF or had undergone heart transplant surgery. New York Heart Association class IV was an exclusion criterion for ICD-only therapy.
Data Collection
Medical records of eligible patients were selected at random to yield an average of ≈90 patients per participating practice. Baseline demographics, clinical characteristics, and diagnostic and laboratory findings were abstracted from patient charts by trained chart review specialists. A rigorous methodology was used in the IMPROVE HF study design to ensure the quality and accuracy of data. Data collection was centrally performed by Outcome Sciences Inc. (Cambridge, MA). All 34 chart review specialists received periodic training under the oversight of the IMPROVE HF steering committee. The average inter-rater reliability between chart reviewers was 0.82 (κ statistic). An average of 1.7 automated data quality checks was performed for each data field to ensure all values met prespecified ranges, formats, and units. Source data verification was randomly performed for 20% of the entire patient sample for 10% of participating practices. In addition, monthly data quality reports were provided to the steering committee.
Statistical Analysis
Descriptive statistics for patient baseline characteristics and practice characteristics by sex were calculated within the ICD/CRT-D cohort and CRT-P/CRT-D cohort. This included mean and SD for continuous variables and frequency and percentage for categorical variables.
Generalized estimating equation (GEE) modeling was used to estimate unadjusted and adjusted relationships between device treatment and patient-level mortality in the first 24 months and to investigate whether the clinical effectiveness of ICD/CRT-D or CRT-P/CRT-D therapy on 24-month mortality would vary by sex. Exchangeable within-practice correlation matrix was used in the modeling to account for correlation of patients from the same cardiology practice. First, for each cohort and men and women within each cohort, clinical benefit of being treated with devices at baseline on 24-month mortality was evaluated using univariate GEE models. In each model, vital status (dead/alive) at 24 months was the outcome and whether being treated with the device at baseline (yes/no) was the predictor. Univariate analysis produced the unadjusted odds ratio (OR) of death and its 95% confidence interval (CI) for device therapy per cohort and per sex-specific subcohort. Furthermore, multivariate GEE models were performed in ICD/CRT-D and CRT-P/CRT-D cohorts separately to determine whether the clinical effectiveness of device therapy on 24-month mortality would be different between men and women, controlling for other baseline patient and practice characteristics. We first screened the characteristics through univariate GEE analysis and included those with P≤0.10 as the covariates for device therapy in initial multivariate GEE models. We then eliminated the covariates with P≥0.05 using backward selection and added sex and race (if not in the reduced models yet) and sex-by-device and race-bydevice interaction terms into the reduced models. The adjusted OR, 95% CI, and P value for device therapy were reported as well as the P value for device-by-sex interaction. The sex-by-device interactions were also examined without race-by-device interactions included. In secondary analyses, univariate and multivariate GEE analyses were also conducted in the ICD-only cohort.
During the first 12 months of the performance initiative, some patients who were eligible for a device therapy cohort yet not treated by it at baseline crossed over and had the device implanted. The crossed over patients were included in the descriptive analysis of baseline characteristics. However, they were excluded from all the GEE analyses to assess the pure relationship between use of device therapy at baseline and vital status at 24 months.
All statistical inference testing was 2 sided with results considered statistically significant at P<0.05. Analyses were completed using SAS statistical software version 9.2 (SAS Institute, Cary, NC).
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Results
A total of 15 177 patients from 167 outpatient cardiology practices in the United States were evaluated at baseline and included in the longitudinal cohort. The records of a median of 90 patients per practice were entered. A total of 11 621 patients (76.6%) had documentation of vital status at the 24-month follow-up. Of them, 7748 were eligible for ICD/ CRT-D and 1188 for CRT-P/CRT-D therapy at baseline. During the first 12 months of performance initiative, 754 ICD/ CRT-D and 165 CRT-P/CRT-D eligible patients who did not carry such devices at baseline had them implanted. After excluding those crossovers, this analysis included a total of 6994 patients from the ICD/CRT-D cohort and 1023 patients from the CRT-P/CRT-D cohort (Figure) . After excluding 1366 patients who had CRT-D in place at baseline from the 6994 ICD/CRT-D patients, the analysis for ICD-only cohort involved 5628 patients.
Baseline patient and practice site characteristics among the ICD/CRT-D eligible cohort were stratified by sex and are listed in Tables 1 and 2. In the ICD/CRT-D eligible cohort (n=7748), there were 71% (n=5485) men and 29% (n=2261) women. Mean age was ≈69 years for both sexes. Ischemic cardiomyopathy was more common among men (75.9%) as the cause of HF than women (57.5%), as was prior myocardial infarction (53.5% versus 39.3%) or coronary artery bypass grafting (38.8% versus 20.7%). Average LVEF was 24.7% for men and 25% for women. Other baseline laboratory and comorbid conditions were similar. The majority of participating practices were nonuniversity, nonteaching (≈66%) with multispecialty clinics (≈75%). Less than 40% had electronic medical health records. Practice characteristics were similar for men and women in the device eligible cohort ( Table 2 ). Of the 5485 men eligible for ICD/CRT-D therapy, 2956 (53.9%) received a device at baseline. Of the 2261 women eligible for ICD/CRT-D therapy, 969 (42.9%) had undergone ICD/CRT-D device placement at baseline.
In the CRT-P/CRT-D eligible cohort (n=1188), there were 824 (69%) men and 364 (31%) women. Mean age was ≈71 years for both sexes. As with the ICD/CRT-D eligible cohort, ischemic cardiomyopathy was more common in men (75.4% versus 57.4%) as was prior myocardial infarction (41.9% versus 29.1%) and history of coronary artery bypass grafting (42.8% versus 20.3%). Mean EF was 23.4% for men and 23.8% for women. Of the 824 men eligible for CRT-P/CRT-D, 37.4% (n=308) received a device at baseline. There was a similar rate of implantation in women with 38.5% (n=140) of the 364 eligible women receiving CRT-P or CRT-D at baseline. Table 3 demonstrates 24-month mortality rates and unadjusted/adjusted ORs for the ICD/CRT-D eligible cohort. Study patients having ICD or CRT-D at baseline were 34% less likely to die at 24 months compared with those not having a device at baseline (20.4% versus 27.8%; OR, 0.66; 95% CI, 0.58-0.74; P<0.0001). Women with ICD or CRT-D at baseline had lower mortality compared with those without baseline devices (18.6% versus 25.5%; OR, 0.65; 95% CI, 0.53-0.79; P<0.0001). On multivariable analysis, the clinical benefit of ICD/CRT-D on mortality remained significant after adjusting for age, sex, race, comorbid conditions including diabetes mellitus, chronic obstructive pulmonary disease, and peripheral vascular disease, New York Heart Association class, edema, LVEF, sodium, blood urea nitrogen, and creatinine (OR, 0.68; 95% CI, 0.56-0.81; P=0.0002). In addition, the test for device-by-sex interaction was not significant (P=0.5966). The findings were similar when race interactions were not considered (P=0.6486) Table 4 demonstrates 24-month mortality rates and unadjusted/adjusted ORs for the CRT-P/CRT-D eligible cohort. Study patients with CRT device therapy at baseline were 37% less likely to die at 2 years compared with those without CRT-P/CRT-D (28.8% versus 38.3%; OR, 0.63; 95% CI, 0.48-0.84; P=0.0017). Both men and women derived associated benefit (men OR, 0.67; 95% CI, 0.49-0.92; P=0.0133; and women OR, 0.53; 95% CI, 0.31-0.91; P=0.0227). On multivariable analysis, the clinical benefit of CRT-P/CRT-D on mortality remained significant after adjusting for age, sex, race, rales, LVEF, diastolic blood pressure, and blood urea nitrogen (adjusted OR, 0.51; 95% CI, 0.3-0.87; P=0.0096). Similar to the ICD/CRT-D eligible cohort, the device-bysex interaction effect was not significant (P=0.4441). The device-by-sex interaction effect was also not significant when device-by-race interactions were not included (P=0.4445). Table 5 demonstrates the clinical effectiveness of ICD-only therapy in men and women. Study patients with baseline ICD therapy were 35% less likely to die at 2 years compared with those without ICD therapy (20.2% versus 27.8%; OR, 0.65; 95% CI, 0.57-0.74; P<0.0001). This association was similar among both men and women with ICD-only therapy (OR, 0.63; 95% CI, 0.54-0.73; P<0.0001 for men; and OR, 0.68; 95% CI, 0.54-0.84; P=0.0005 for women). Multivariate GEE analysis demonstrated that the clinical benefit of ICD-only therapy persisted after adjusting for age, race, comorbid conditions (chronic obstructive pulmonary disease and peripheral vascular disease), New York Heart Association class, edema, LVEF, systolic blood pressure, sodium, blood urea nitrogen, and creatinine for the overall cohort (OR, 0.73; 95% CI, 0.60-0.89; P=0.0032) and was similar for both men and women (Table 5 ). Again, device-by-sex interaction effect was not significant in this ICD-only cohort (P=0.9808).
Discussion
Among the 6994 patients with HF and reduced EF being treated at outpatient cardiology/multispecialty practices who were eligible for ICD/CRT-D and 1023 patients eligible for CRT-P/CRT-D without crossover, the clinical benefit associated with ICD or CRT was substantial. Study patients with device therapy at baseline had a lower likelihood of death at 24 months compared with those without baseline device therapy. Multivariate analysis revealed that the mortality benefit of baseline device therapy persisted after adjusting for baseline characteristics. Importantly, ICD and CRT therapy was associated with significant survival benefit in women, and the analysis of device-by-sex interaction was not statistically significant (P=0.4441 for CRT-P/CRT-D, P=0.5966 for ICD/CRT-D, and P=0.9808 for ICD only), signifying that the clinical benefit of device therapy is not driven by sex among outpatients with HF. Prior studies have shown mortality benefit for ICD therapy and CRT. In the MADIT-CRT trial, which compared CRT-D with ICDs alone, the superiority of CRT was driven by a 41% reduction in the risk of HF events, a finding that was evident primarily in a prespecified subgroup of patients with a QRS duration of ≥150 ms. There was no difference in mortality between those with CRT and those without after 4.5 years of follow-up. However, a sex-specific outcome analysis in the MADIT-CRT trial demonstrated that women with CRT-D therapy obtained significantly greater reductions in HF and all-cause mortality compared with men. Some have postulated that the clinical effectiveness may reflect the higher presence of left bundle branch block among women study participants, 3 and the benefit associated with ICD/CRT-D use in MADIT-CRT trial may have been driven by CRT being more effective in women compared with men.
In our study, notably, QRS duration was similar between men and women in both the ICD and CRT-D cohorts. In addition, to determine whether clinical benefit observed in women and men in this cohort was because of CRT or ICD therapy, we performed an analysis of ICD-only study patients. Among this cohort of outpatients with HF, the mortality benefit from device therapy was not driven by CRT alone because the ICDonly analysis yielded a clinically and statistically significant reduction in events. Importantly, the clinical effectiveness of ICD did not vary by sex.
These results have important clinical implications for the management of patients with HF with reduced EF. With the expanding evidence base provided by clinical trials, the number of guideline-recommended HF therapies has increased. This increase has been considered by some to place additional burdens on patients in terms of adherence and physicians and on health systems in terms of resource allocation. Because women have historically been under-represented in clinical trials of CRT/ICD therapy, whether this important patient population benefits to a similar degree with device therapy as men has been questioned. In the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial, a reduction in all-cause mortality was seen in men, but not for women receiving ICD therapy. 22 However, when performing sex-specific analyses for interaction, no difference was found, although this analysis was likely underpowered because there were only 132 women enrolled in the study. 23 As previously mentioned, the SCD-HeFT trial demonstrated a smaller ICD benefit among women. However, the test for an interaction between sex and therapy was not significant. In addition, the lower overall mortality risk among women in the placebo group and the fact that only 23% of study participants were women may explain why treatment differences were difficult to detect. 12 To our knowledge, the present study is among the largest studies to address the question of sex-specific benefits with ICD therapy or CRT. Our data support the need for sex-specific outcome reporting and refute any meaningful differences in clinical effectiveness as a function of sex for either ICD or CRT-D therapy. These findings reinforce current American College of Cardiology/American Heart Association HF guidelines which assign a class I recommendation that groups of patients including women, even if under-represented in clinical trials, should, in the absence of specific evidence to treat otherwise, have clinical screening and therapy in a manner identical to that provided to the broader HF population. These data may help to further lessen disparate care as a function of sex in patients with HF eligible for device therapy.
Limitations
The design of IMPROVE HF has some inherent limitations that may affect the interpretation of findings. Specifically, patient data were collected by medical chart review, which is dependent on the accuracy and completeness of documentation. Some patients considered eligible for treatment who were not treated may have had contraindications or other reasons that prevented treatment but were not documented in the medical record. The implantation rate of ICDs in eligible patients at baseline was lower in women than in men, which may introduce selection bias. Follow-up on vital status was not achieved for all patients. This analysis was confined to patients with complete follow-up at 24 months, and patients with early crossover to treatment were excluded from analysis, which may have also introduced bias. We did not assess health-related quality of life, symptom control, functional capacity, patient satisfaction, hospitalization rates, or other clinical outcomes that may be of interest. As with all observational studies, the possibility for residual measured or unmeasured confounding exists potentially leading to overestimation or underestimation of treatment effects. The associations of device use with outcomes do not determine causality and may reflect treatment selection bias. We could not adjust for socioeconomic factors. The majority of patients who received CRT received a CRT-D device, preventing analysis of the association of CRT-P with outcomes. The guidelines for CRT have been recently revised and use criteria that differ in some ways from those in place during the study. Although patients in IMPROVE HF were selected from a representative sample from each practice, enrollment required documented left ventricular function and ≥2 office visits with a cardiologist in the past 2 years, which may have introduced some ascertainment bias. These findings may not apply to practices that differ in patient-case mix, baseline care patterns, motivation, resources, and other factors from those that agreed to participate in IMPROVE HF.
Conclusions
In this large outpatient cohort of patients with chronic HF treated at cardiology/multispecialty practices participating in a performance improvement initiative, the use of guidelinedirected CRT and ICD therapy was associated with substantially reduced 24-month mortality in eligible men and women with HF and reduced EF. Our data did not show any meaningful differences in clinical effectiveness as a function of sex for either ICD therapy or CRT. These findings have important clinical implications and indicate that CRT-D and ICD therapies should be offered to all eligible patients with HF and reduced EF, without modification based on sex.
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